Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1906 to 1920 of 7682 results

  1. Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg TS ID 11894

      Status ...

    Technology appraisal guidance
    Topic selection

  2. TAK-880 for managing primary immunodeficiency diseases in people hypersensitive to IgA TS ID 11883

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development [GID-TA11198] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    Awaiting development [GID-TA11130] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Arthrosamid for symptomatic treatment of knee osteoarthritis

      Status ...

    Medical technologies guidance
    Topic selection

  6. Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642

    Awaiting development [GID-TA11308] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147

    Awaiting development [GID-TA11327] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550

    Awaiting development [GID-TA11354] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over TS ID 11865

    Awaiting development [GID-TA11358] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    Awaiting development [GID-TA10868] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Renal cell carcinoma Pathways Pilot [ID6186]

    In development [GID-TA11186] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Deucravacitinib for treating active psoriatic arthritis TS ID 11981

    Awaiting development [GID-TA11510] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970

    Awaiting development [GID-TA11502] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977

    Awaiting development [GID-TA11507] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400

    Awaiting development [GID-TA11509] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development